Save up to 90% on Tafamidis Meglumine with Coupons, Discount Cards & Patient Assistance Programs

Tafamidis Meglumine is available as a 20 mg oral capsule.

Tafamidis Meglumine is a transthyretin (TTR) stabilizer that is used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, a rare heart muscle disease).

Tafamidis Meglumine is a transthyretin (TTR) stabilizer. It works by attaching to a protein in your body called transthyretin. This slows protein breakdown and buildup in the heart walls, which makes it easier for the heart to pump blood to the rest of your body.

Tafamidis Meglumine is typically taken as 80 mg by mouth once daily.

Tafamidis Meglumine is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Tafamidis Meglumine:

• Bone, muscle, or joint problems
• Injury
• Skin problems
• Heart failure
• Falls
• Mental health problems
• Atrial fibrillation
• Shortness of breath
• Swelling of the hands, feet, or ankles
• Tiredness
• Dizziness
• Eye problems
• Constipation

Serious side effects are rare with Tafamidis Meglumine.

The following medications may interact with Tafamidis Meglumine:

• Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate

Various FDA-approved generic manufacturers

Tafamidis Meglumine may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Tafamidis Meglumine or VYNDAMAX. You may also report your pregnancy by calling the Pfizer reporting line at 1-800-438-1985.

• Vyndaqel